BioStock: Additional data strengthens Cereno’s CS1 in PAH

Following the promising phase IIa results for its drug candidate CS1 in pulmonary arterial hypertension (PAH) in the fall of 2024, Cereno Scientific now delivers comprehensive data that further reinforce the candidate’s potential.  The completed clinical study report shows further signs of disease-modifying effects in a disease with limited treatment options. 

Read the article at biostock.se:

https://www.biostock.se/en/2025/02/additional-data-strengthens-cerenos-cs1-in-pah/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/